Epigenetic Market major players New England Biolabs, Inc., Thermo Fisher Scientific, Inc.

Epigenetic procedure involves stable changes in genome, which are reversible in gene expression. These changes can be transferred generation to generation, but contains no permanent changes in DNA. The epigenetically controlled genes are repressed or activated with no genotypic change in DNA. Epigenetic changes occur phenotypically but will have no genotypic change in the gene. This changes can occur naturally but can also be initiated by the environment changes, aging, lifestyle and some disease conditions. The Epigenetic procedures end up having both positive as well as damaging results. Positive expression results in differentiation of cells like skin cells, liver cells, pancreatic cells and lung cells etc. and the damaging expression of epigenetic changes can leads to formation of different cancer cells.

The epigenetic process includes phosphorylation, methylation, sumolyation, acetylation and ubiquitylation etc. of DNA as well as histones resulting in changes in Phenotypes. These changes are modified with environmental conditions. Epigenetic market is now an emerging field. There are various diagnostic tests available now that detect epigenetic changes. There are some FDA approved epigenetic drugs. Other than many diagnostic companies, many biopharmaceutical and pharmaceutical companies are also very active in the field of epigenetic. The worldwide ongoing research in finding the role of epigenetic in different disease and disorders is fueling the epigenetic market. Within the diagnostic segment of the epigenetic, most of the focus has been on the detection of DNA methylation. Most of the activity and interest of the companies is focused on the therapeutic segment of the epigenetic field.

Request Report Sample@ https://www.persistencemarketresearch.com/samples/11719

The global market for epigenetic device market is expected to be driven by the advancement in technology. The key drivers of the market are the increasing cases prevalence of cancer, growing ageing population and increase in obese population. Moreover, the increasing research activities, increasing research on oncology diseases and the growing collaboration between research institutes, Biotechnology and Biopharmaceuticals companies is also acting as a fuel to the market and is expected to drive the market within the forecast period of 2016-2026. However, the high cost of the procedures and the lack of fund can be the restraint for the growth of this market.

The Epigenetics market is classified on the basis of product, end user and geography.

Based on the Product, the global epigenetic market is segmented into the following:

Enzyme
DNA modifying Enzymes
RNA modifying Enzymes
Protein Modifying Enzymes
Kits
ChIP-seq Kits
Genome Amplification kits
Bisulfite Conversion Kits
Sequencing kits
5-hmC and 5-mC Analysis Kits
Others
Reagents
Buffers
Antibiotics
Primers
Histones
Others

Based on end user, the global Epigenetic market is segmented into the following:

Academic Research Institutes
Biotechnology Companies
Biopharmaceutical Companies
Diagnostic Companies
Contract Research Organizations

The number of companies developing methods to detect modification in DNA due to methylation has not significantly changed in recent years. The increasing investment by the pharmaceutical and Biotechnology companies is expected to drive the market. Based on the product type the market is segmented to Enzymes, Kits and Reagents. The enzymes are further classified to DNA modifying enzyme that includes all DNA ligase and DNA polymerase. RNA modifying enzyme includes all methyltransferases and acetylases. RNA modifying enzymes includes Reverse ligases and Reverse Transcriptase.

By end user, the global epigenetic market has been segmented into Academic research institutes, Biotechnology Companies, Biopharmaceutical Companies, Diagnostic Companies and Contract Research Organizations. Epigenetic procedures are performed in many research oriented areas such as developmental biology, oncology, drug discovery and others.

By regional presence, Epigenetic market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the Epigenetic market for due to high availability of funding for research. Europe is expected to hold second largest market share in global Epigenetic market. The growing government initiatives and increasing number of Biotechnology and Biopharmaceutical companies in APAC is also driving the market of epigenetic in APAC.

Some of the major players in global epigenetic market include Illumina, Inc., QIAGEN N.V., Abcam plc., Merck & Co., Sigma-Aldrich Corporation, New England Biolabs, Inc., Thermo Fisher Scientific, Inc., Diagenode, Inc. and Active Motif and others.

Visit For TOC@ https://www.persistencemarketresearch.com/toc/11719

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
Telephone - +1-646-568-7751
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.